Permanent Cure for Baldness? Inside the Google-Backed Quest to Awaken Sleeping Hair Follicles

Part I: The End of an Age-Old Resignation

More Than Just Hair – The Psychological Weight of Alopecia

For millennia, the slow, creeping retreat of a hairline has been a source of quiet resignation and, for many, profound distress. Hair loss, or alopecia, is a near-universal human experience, affecting up to 80% of men and 40% of women over their lifetimes. It is far more than a simple cosmetic inconvenience; it is a medical condition with a significant psychological toll, often impacting self-esteem and mental well-being. The global market for hair loss prevention products, a testament to this deep-seated concern, was valued at over $23 billion in 2021 and is projected to climb past $31 billion by 2028.   

This vast market is saturated with treatments ranging from questionable “miracle” lotions to legitimate, albeit limited, medications. For decades, the frontline of this battle has been held by two FDA-approved drugs: minoxidil (Rogaine) and finasteride (Propecia). While they have offered a glimmer of hope, their effectiveness is often partial, inconsistent, and comes with potential side effects. Many users find themselves fighting a defensive war, slowing the loss or coaxing the growth of fine, wispy “vellus” hairs rather than achieving true restoration.   

This long history of partial victories and persistent frustration is precisely why a recent breakthrough from a team of scientists at the University of California, Los Angeles (UCLA) has generated such intense excitement. They have not just developed another weapon for the existing arsenal; they have unveiled a fundamentally new strategy. Their work suggests a future where we no longer just manage hair loss but may be able to reverse it by awakening the body’s own dormant regenerative power. This is the story of a molecule that could restart an engine that was never truly broken, just switched off.   

The UCLA Triumvirate: A Convergence of Minds

The origin of this potential revolution lies not in a dedicated hair loss clinic, but at the intersection of three distinct and powerful scientific disciplines, embodied by a trio of UCLA researchers: William Lowry, Heather Christofk, and Michael Jung. Their collaboration represents a perfect storm of expertise, and remarkably, their groundbreaking discovery in hair restoration was an elegant byproduct of their primary research into the fundamental mechanisms of cancer and stem cell biology.   

William Lowry, Ph.D., is a professor of molecular, cell, and developmental biology and a leading expert in stem cells.His laboratory has long focused on how adult stem cells, particularly the hair follicle stem cells (HFSCs), are regulated. These cells are responsible for the cyclical regeneration of hair, and understanding their behavior is critical. Dr. Lowry’s research delved into how these stem cells maintain tissue and how that process can go awry, leading to cancers like squamous cell carcinoma. It was during this deep dive into the basic biology of the hair follicle that his lab uncovered a unique metabolic profile that governs whether these stem cells are active or dormant.   

Heather Christofk, Ph.D., is a professor of biological chemistry and a maestro of cellular metabolism. Her work explores how cells—from virally infected cells to cancer cells—reprogram their metabolism to fuel their specific needs, whether it be rapid division or survival. Dr. Christofk’s research established a bi-directional relationship: a cell’s state changes its metabolism, but conversely, changing a cell’s metabolism can drive a change in its state. This concept proved to be the lynchpin. By collaborating with Dr. Lowry, she helped decipher the specific metabolic processes that keep hair follicle stem cells “asleep” and, crucially, how to manipulate those processes to wake them up.   

Michael Jung, Ph.D., is a distinguished professor of chemistry and a master molecule builder. A world-renowned medicinal chemist, Dr. Jung specializes in designing and synthesizing novel molecules to serve as drugs for a vast range of human diseases. His credibility is immense; he is a co-inventor of two blockbuster, FDA-approved prostate cancer drugs, enzalutamide (Xtandi) and apalutamide (Erleada). When Lowry and Christofk identified the biological target for reawakening hair follicles, it was Jung’s expertise that allowed them to design and create the precise molecular key to fit that lock: a small molecule that could effectively and safely execute the desired biological command.   

This convergence of expertise—in stem cell biology, cellular metabolism, and medicinal chemistry—allowed the team to identify a biological target, understand its function, and design a drug to manipulate it. The result is a molecule they dubbed PP405.   

Part II: The Science of Resurrection: How to Wake a Sleeping Follicle

The “Metabolic Switch”: It’s Not Magic, It’s Metabolism

The core innovation behind PP405 is a radical departure from previous hair loss treatments. It doesn’t focus on external factors like hormones or blood flow. Instead, it works from the inside out, targeting the fundamental energy-producing machinery within the hair follicle stem cells themselves.   

The central discovery is that in common forms of hair loss, such as androgenetic alopecia, the hair follicle stem cells are not dead or absent; they are simply “stuck” in a dormant or quiescent state, known as the telogen phase of the hair cycle.Imagine an engine that is perfectly functional but has been switched off. Previous treatments have tried to push the car or improve the fuel line, with limited success. The UCLA team found the ignition switch.   

This switch is a metabolic one. Regenerating cells, like those active in a growing hair follicle, have a distinct metabolic signature. They favor a rapid, oxygen-independent energy production process called glycolysis. Dormant cells, by contrast, tend to rely on a more efficient, oxygen-dependent process within the mitochondria. The key to waking the dormant stem cells, the researchers found, was to force them to switch their metabolic preference back to the regenerative, glycolytic state.   

This is precisely what PP405 does. It is a potent inhibitor of a protein called the mitochondrial pyruvate carrier (MPC).The MPC acts as a gatekeeper, controlling the entry of pyruvate—a key fuel molecule derived from glucose—into the mitochondria. By blocking this gate, PP405 effectively starves the mitochondria of their primary fuel source. This forces the cell to ramp up glycolysis in the main body of the cell to generate energy, producing lactate as a byproduct. This metabolic shift, characterized by increased activity of the enzyme lactate dehydrogenase (LDH), mimics the state of highly active, proliferative stem cells. This change in the internal environment acts as an unambiguous signal for the dormant hair follicle stem cell to re-enter the growth (anagen) phase and begin the process of producing a new hair fiber.   

This approach is what defines PP405 as a true “regenerative medicine” therapy. It is not masking a symptom or fighting an external aggressor; it is reactivating the body’s own innate capacity to grow hair.   

The Old Guard vs. The New Paradigm: A Head-to-Head Comparison

To fully appreciate the significance of PP405, it is essential to contrast its mechanism with the two most common FDA-approved treatments: minoxidil and finasteride. For decades, these have been the only scientifically validated options, but they operate on entirely different principles and come with their own sets of limitations.   

Minoxidil (Rogaine) was originally an oral medication for high blood pressure. Its hair-growing properties were an accidental discovery. Its exact mechanism is still not fully understood, but it is known to be a vasodilator, meaning it widens blood vessels, which may improve blood and nutrient flow to the follicle. It is also a potassium channel opener, which is thought to help shorten the resting phase and prolong the growth phase of the hair cycle. However, its effects are often modest, sometimes producing only fine, “peach fuzz” hair, and it does not address the underlying cause of follicular dormancy.   

Finasteride (Propecia) works by tackling the hormonal cause of male pattern baldness. It is a 5-alpha-reductase inhibitor, an enzyme that converts testosterone into the more potent androgen, dihydrotestosterone (DHT). In genetically susceptible individuals, DHT binds to receptors in the hair follicles, causing them to shrink (miniaturize) and eventually stop producing hair. By reducing DHT levels, finasteride can halt this process and, in some cases, reverse it. Its primary limitation is its hormonal mechanism; it is an oral drug with systemic effects and is not suitable for women. Some men also experience sexual side effects.   

PP405 represents a new paradigm. It bypasses the hormonal pathways targeted by finasteride and the poorly understood vascular effects of minoxidil. Because it targets a fundamental metabolic process common to all hair follicle stem cells, it holds the potential to be effective for both men and women, across all hair and skin types, without systemic hormonal disruption.   

Part III: The Gauntlet: From Lab Bench to Human Scalps

Decoding the Data – The Clinical Trial Journey

A promising scientific theory is one thing; proving it works safely and effectively in humans is another. The journey of PP405 from the lab bench to the medicine cabinet is a story told through the rigorous, multi-stage process of clinical trials. The data emerging from these trials has been the driving force behind the growing excitement and investment.

The initial myth of a “one-week cure” stems from a misunderstanding of the trial phases. The first human study, Phase 1, was designed primarily to test for safety, tolerability, and, critically, proof of mechanism. In this trial, participants applied a 0.05% PP405 topical gel for just seven days. The results were pivotal: the treatment was found to be safe and well-tolerated, with no detectable absorption into the bloodstream, confirming its localized action. Most importantly, biopsies of the treated scalp tissue showed a statistically significant increase in   

Ki67, a well-established molecular marker for cell proliferation. This was the smoking gun. In just one week, PP405 had successfully “flipped the switch” and told the dormant stem cells to start dividing. It proved the science worked in humans.   

This successful proof of mechanism was the green light for the Phase 2a trial, which began in mid-2024. This phase is designed to evaluate safety in a larger group and to look for the first real signs of   

efficacy—actual hair growth. The trial enrolled 78 men and women with androgenetic alopecia, including a diverse range of skin and hair types, a conscious effort to ensure broad applicability. In this study, participants applied the gel daily for four weeks and were monitored for up to 12 weeks.   

The early results from this Phase 2a trial, announced in mid-2025, were nothing short of stunning and are what truly propelled PP405 into the spotlight. Among men with a higher degree of hair loss, 31% of those treated with PP405 showed a greater than 20% increase in hair density just eight weeks after starting the trial (four weeks after treatment ended). By contrast, 0% of the placebo group saw such an improvement. This result is remarkable for two reasons. First, the magnitude of the response in a significant portion of the treatment group is highly encouraging. Second, the speed is unprecedented. Visible results from existing treatments like minoxidil or finasteride typically require 6 to 12 months of continuous use. PP405 demonstrated a measurable, significant effect in a fraction of that time, suggesting a powerful and rapid regenerative capability.   

The Pelage Powerhouse and the Google Stamp of Approval

The translation of this groundbreaking UCLA research into a potential commercial product is being managed by Pelage Pharmaceuticals, a startup co-founded by the scientific trio of Lowry, Christofk, and Jung. The company was formed through UCLA’s Technology Development Group, which helps shepherd brilliant academic discoveries into the marketplace, and exclusively licensed the intellectual property for PP405 and related molecules in 2018.   

The trajectory of Pelage demonstrates a powerful, virtuous cycle where strong science attracts significant capital, which in turn accelerates further research. The initial promise of the science was enough to get the company off the ground. However, the real catalyst was the positive data from the clinical trials.

In February 2024, on the back of promising preclinical work and the initiation of the Phase 1 trial, Pelage announced it had closed a $16.75 million Series A financing round led by GV (formerly Google Ventures), with participation from other key investors. This investment from one of Silicon Valley’s most respected venture capital firms was a massive vote of confidence. Cathy Friedman, Executive Venture Partner at GV and a Pelage board member, noted, “GV is excited by the incredible science behind the Pelage technology… moving beyond agents that merely slow the progression of hair loss to a treatment solution that actually helps to regrow hair”.   

The validation loop then spun faster. Following the release of the successful Phase 1 data demonstrating safety and the crucial Ki67 activation, Pelage secured an additional $14 million in a Series A-1 financing round in August 2024, again led by GV. This new infusion of capital was explicitly earmarked to “accelerate its Phase 2 clinical program”. This sequence of events is a clear illustration of how the modern biotech ecosystem functions: robust, data-driven scientific validation unlocks the financial resources necessary to navigate the long and expensive path of clinical development and regulatory approval. The GV stamp of approval is more than just money; it is a powerful endorsement of the quality of the science and the potential of the technology to disrupt a multi-billion dollar market.   

Part IV: The Horizon and Beyond

The Road to the Medicine Cabinet: Timelines, Trials, and Tribulations

While the early data is exceptionally promising, PP405 is not yet ready for public use. The path to the medicine cabinet is a marathon, not a sprint, governed by the rigorous safety and efficacy standards of the U.S. Food and Drug Administration (FDA).

Following the current Phase 2a trial, Pelage Pharmaceuticals will need to conduct a larger, more definitive Phase 3 trial. This phase typically involves hundreds or even thousands of patients and is designed to confirm the efficacy and safety observed in earlier trials on a much larger scale. This is the final and most expensive step before a company can submit a New Drug Application (NDA) to the FDA for approval.

Given the standard timelines for these processes, industry experts and the company project that a PP405-based treatment could potentially reach the market between 2027 and 2030, pending successful outcomes in all remaining trials.   

An interesting note in the public trial registry is the mention of “Expanded Access”. This is a potential pathway through which patients with serious or immediately life-threatening conditions who cannot participate in a clinical trial may gain access to an investigational drug outside of the trial setting. While hair loss is not typically considered life-threatening, this provision indicates a mechanism exists for specific cases, though its application here remains to be seen.   

Crucially, the potential impact of PP405 may extend far beyond common pattern baldness (androgenetic alopecia). Because its mechanism targets the fundamental biology of the hair follicle stem cell—waking it from dormancy—it is agnostic to what caused the dormancy in the first place. This has led researchers and the company to investigate its potential for other types of hair loss. Pelage is actively developing PP405 for chemotherapy-induced alopecia and believes it may also have applications for telogen effluvium, or stress-induced hair loss. This transforms PP405 from a single product into a potential platform technology, capable of addressing a wide spectrum of alopecia conditions and dramatically expanding its medical and commercial significance.   

The Regenerative Revolution: If We Can Awaken Hair, What’s Next?

Zooming out from the immediate goal of curing baldness, the story of PP405 offers a tantalizing glimpse into the future of medicine. The core principle—using a small molecule to reprogram the metabolism of a dormant stem cell to trigger a regenerative process—is a landmark achievement. It serves as a powerful proof-of-concept for a new therapeutic strategy.  

The human body is replete with slumbering or hibernating cells in various tissues—cells that are not dead, but are no longer active. The questions that PP405 raises are profound. If we have found the molecular “alarm clock” for hair follicle stem cells, can we find similar keys for other cell types? Could we, in the future, awaken dormant cardiac cells to repair a damaged heart, or neural stem cells to restore function after a stroke?   

This is the grand promise of regenerative medicine: shifting the focus from treating symptoms or blocking disease pathways to actively restoring the body’s own incredible, innate ability to heal and rebuild itself. The work of Lowry, Christofk, and Jung began as an inquiry into the fundamental rules of life, cancer, and metabolism. It has resulted in a potential solution to one of humanity’s most common afflictions. But its true legacy may be even greater. It may be remembered not just for the hair it regrew, but for the new chapter it opened in our quest to unlock the restorative power hidden within our own cells.

References

1. Bauman Medical. (2025). Pelage PP405 Stimulates Hair Follicle Stem Cells via Mitochondria in Phase 1 Trial. Retrieved from https://www.baumanmedical.com/pelage-pp405-stimulates-hair-follicle-stem-cells-via-mitochondria-in-phase-1-trial/   
2. Buhl, A. E., Waldon, D. J., Baker, C. A., & Johnson, G. A. (1990). Minoxidil sulfate is the active metabolite that stimulates hair follicles. Journal of Investigative Dermatology, 95(5), 553–557. https://doi.org/10.1111/1523-1747.ep12504905   
3. Business Wire. (2025, June 17). Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy. Retrieved from https://www.businesswire.com/news/home/20250617338859/en/Pelage-Pharmaceuticals-Announces-Positive-Phase-2a-Clinical-Trial-Results-for-PP405-in-Regenerative-Hair-Loss-Therapy   
4. ClinicalTrials.gov. (2025). Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (Identifier NCT06393452). U.S. National Library of Medicine. Retrieved from https://clinicaltrials.gov/study/NCT06393452   
5. DrugTopics. (2025). Hair Loss Therapy Shows Potential for Regeneration in Phase 2 Trial. Retrieved from https://www.drugtopics.com/view/hair-loss-therapy-shows-potential-for-regeneration-in-phase-2-trial   
6. Finsmes. (2024, August). Pelage Pharmaceutical Raises $14M Series A-1 Funding. Retrieved from https://www.finsmes.com/2024/08/pelage-pharmaceutical-raises-14m-series-a-1-funding.html   
7. Gupta, A. K., & Charrette, A. (2023). The role of finasteride in the treatment of androgenetic alopecia. Journal of Dermatological Treatment, 34(1), 2154231.   
8. iHeart. (2025, May 15). New UCLA Discovery Could Help Regrow Real Hair by 2027. Retrieved from https://www.iheart.com/content/2025-05-15-new-ucla-discovery-could-help-regrow-real-hair-by-2027/   
9. Messegué, F., et al. (2022). Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti-androgens. Dermatologic Therapy, 35(10), e13059. https://doi.org/10.1111/dth.13059   
10. Messenger, A. G., & Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology, 150(2), 186–194. https://doi.org/10.1111/j.1365-2133.2004.05785.x   
11. Pelage Pharmaceuticals. (n.d.). A New Approach to Hair Loss Grounded in Stem Cell Biology. Retrieved from https://pelagepharma.com/   
12. PR Newswire. (2024, February 27). Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss. Retrieved from https://www.prnewswire.com/news-releases/pelage-pharmaceuticals-announces-16-75m-series-a-financing-led-by-gv-to-revolutionize-regenerative-medicine-for-hair-loss-302071733.html   
13. PR Newswire. (2024, March 9). Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study. Retrieved from https://www.prnewswire.com/news-releases/pelage-presents-late-breaking-data-at-aad-2024-meeting-demonstrating-pp405-activates-human-hair-follicle-stem-cells-ex-vivo-and-in-phase-1-clinical-study-302084610.html   
14. StatPearls. (2023). Androgenetic Alopecia. NCBI Bookshelf. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK430924/   
15. Stubbs Alderton & Markiles, LLP. (2024). SA&M Client Pelage Pharmaceuticals Secures $14M Series A-1 Financing. Retrieved from https://stubbsalderton.com/sam-client-pelage-pharmaceuticals-secures-14m/   
16. Synapse. (n.d.). Pelage Pharmaceuticals Reports Positive Phase 2a Trial Results for PP405 in Hair Loss Therapy. PatSnap. Retrieved from https://synapse.patsnap.com/article/pelage-pharmaceuticals-reports-positive-phase-2a-trial-results-for-pp405-in-hair-loss-therapy   
17. Synapse. (n.d.). Pelage secures $14M from GV, starts Phase II for alopecia. PatSnap. Retrieved from https://synapse.patsnap.com/article/pelage-secures-14m-from-gv-starts-phase-ii-for-alopecia   
18. UCLA Broad Stem Cell Research Center. (n.d.). Heather Christofk, Ph.D. Profile. Retrieved from https://stemcell.ucla.edu/member-directory/heather-christofk-phd   
19. UCLA Broad Stem Cell Research Center. (n.d.). Michael E. Jung, Ph.D. Profile. Retrieved from https://stemcell.ucla.edu/member-directory/michael-e-jung-phd   
20. UCLA Broad Stem Cell Research Center. (n.d.). William Lowry, Ph.D. Profile. Retrieved from https://stemcell.ucla.edu/member-directory/william-lowry-phd   
21. UCLA Newsroom. (2019, May 28). UCLA licenses technology to combat hair loss to company founded by faculty members. Retrieved from https://newsroom.ucla.edu/releases/hair-loss-drug-formula-licensed   
22. UCLA Newsroom. (2025, February 4). Did UCLA just cure baldness?. UCLA Magazine. Retrieved from https://newsroom.ucla.edu/magazine/baldness-cure-pp405-molecule-breakthrough-treatment   
23. Various Authors. (n.d.). Mechanism of action of minoxidil for hair loss. PubMed. Retrieved from various sources.